{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:05:25Z","timestamp":1788433525991,"version":"build-2803163510"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.2215\/cjn.13641217","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T10:40:21Z","timestamp":1529059221000},"page":"1030-1036","source":"Crossref","is-referenced-by-count":15,"title":["Heroin Use Is Associated with AA-Type Kidney Amyloidosis in the Pacific Northwest"],"prefix":"10.2215","volume":"13","author":[{"given":"Arjun","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Toukatly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Senter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Najafian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kestenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"B1-20230601","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis.","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"B2-20230601","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA amyloidosis: Pathogenesis and targeted therapy.","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"B3-20230601","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/00062752-200001000-00012","article-title":"Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states.","volume":"7","author":"Urieli-Shoval","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"B4-20230601","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.144.4.1121","article-title":"Murine model for human secondary amyloidosis: Genetic variability of the acute-phase serum protein SAA response to endotoxins and casein.","volume":"144","author":"McAdam","year":"1976","journal-title":"J Exp Med"},{"key":"B5-20230601","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis.","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"B6-20230601","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-91-1-26","article-title":"Amyloidosis in chronic heroin addicts with the nephrotic syndrome.","volume":"91","author":"Scholes","year":"1979","journal-title":"Ann Intern Med"},{"key":"B7-20230601","first-page":"195","article-title":"AA protein-related renal amyloidosis in drug addicts.","volume":"112","author":"Menchel","year":"1983","journal-title":"Am J Pathol"},{"key":"B8-20230601","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0002-9343(86)90550-4","article-title":"Amyloidosis in subcutaneous heroin abusers (\u201cskin poppers\u2019 amyloidosis\u201d).","volume":"81","author":"Neugarten","year":"1986","journal-title":"Am J Med"},{"key":"B9-20230601","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/qjmed\/hcl092","article-title":"Renal amyloidosis in intravenous drug users.","volume":"99","author":"Connolly","year":"2006","journal-title":"QJM"},{"key":"B10-20230601","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2369-13-151","article-title":"Renal AA-amyloidosis in intravenous drug users--a role for HIV-infection?","volume":"13","author":"Jung","year":"2012","journal-title":"BMC Nephrol"},{"key":"B11-20230601","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/nep.12616","article-title":"Characteristics of AA amyloidosis patients in San Francisco.","volume":"21","author":"Lejmi","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"B12-20230601","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/msj.21342","article-title":"AA amyloidosis: Mount Sinai experience, 1997-2012.","volume":"79","author":"Bunker","year":"2012","journal-title":"Mt Sinai J Med"},{"key":"B13-20230601","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/93.8.535","article-title":"Presentation, survival and prognostic markers in AA amyloidosis.","volume":"93","author":"Joss","year":"2000","journal-title":"QJM"},{"key":"B14-20230601","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13506129.2017.1338565","article-title":"Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis.","volume":"24","author":"Kuroda","year":"2017","journal-title":"Amyloid"},{"key":"B15-20230601","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B17-20230601","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1556-4029.2007.00452.x","article-title":"Necrotizing fasciitis: Manifestations, microbiology and connection with black tar heroin.","volume":"52","author":"Dunbar","year":"2007","journal-title":"J Forensic Sci"},{"issue":"Suppl 1","key":"B18-20230601","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13506129.2011.574354085","article-title":"The changing face of AA amyloidosis: A single center experience.","volume":"18","author":"Girnius","year":"2011","journal-title":"Amyloid"},{"key":"B19-20230601","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2215\/CJN.10491012","article-title":"Renal amyloidosis: Origin and clinicopathologic correlations of 474 recent cases.","volume":"8","author":"Said","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230601","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0272-6386(89)80041-1","article-title":"Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis.","volume":"13","author":"Crowley","year":"1989","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201807000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:01Z","timestamp":1786369081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201807000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13641217","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]}}}